Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3913]

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in...

Dr Sara Hurvitz - University of California, Los Angeles, USA

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC ( Dr Sara Hurvitz - University of California, Los Angeles, USA )

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning

Dr Shernan Holtan - University of Minnesota, Minneapolis, USA

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning ( Dr Shernan Holtan - University of Minnesota, Minneapolis, USA )

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response...

Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib, venetoclax and obinutuzumab show high rates of clinical response in previously untreated CLL enriched for high-risk disease ( Dr Christine Ryan - Dana-Farber Cancer Institute, Boston, USA )

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and...

Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC ( Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA )

Camizestrant may be superior to fulvestrant in patients with hormone receptor...

Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer ( Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain )

An analysis of the worldwide utilisation of haematopoietic stem cell...

Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA

An analysis of the worldwide utilisation of haematopoietic stem cell transplantation for acute myeloid leukaemia ( Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA )

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in...

Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC ( Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India )

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows...

Dr Emma Searle - University of Manchester, Manchester, UK

Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma ( Dr Emma Searle - University of Manchester, Manchester, UK )

HER2DX confirms the ability of the test to predict long-term survival and...

Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain

HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC ( Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain )

Treatment decision guided by CTC count may improve long-term outcomes for mBC

Prof Jean-Yves Pierga - Institut Curie, Paris, France

Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )

More from ecancer